FrankSCzerwiecJr.MDPhD(He/Him)
[Pronunciation: Chair-V-etz]
Endocrinology • Coconut Grove, FLDiabetes, Lipid Metabolism
Chief Medical Officcer, Sparrow Pharma
Dr. Czerwiec is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2675 S Bayshore Dr
Suite 1103S Clinical Development
Coconut Grove, FL 33133
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1994 - 1997
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1990 - 1994
University of Miami Leonard M. Miller School of MedicineClass of 1990
Certifications & Licensure
MD State Medical License 1994 - 2026
VA State Medical License 1994 - 2024
Clinical Trials
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Start of enrollment: 2007 Jan 01
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Start of enrollment: 2010 Oct 01
- Tolvaptan Extension Study in Participants With ADPKD Start of enrollment: 2010 May 26
- Join now to see all
Publications & Presentations
PubMed
- 1024 citationsTolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham
The New England Journal of Medicine. 2012-12-20 - 790 citationsTolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.Robert W. Schrier, Peter Gross, Mihai Gheorghiade, Tomas Berl, Joseph G. Verbalis
The New England Journal of Medicine. 2006-11-16 - 151 citationsPrevalence of autosomal dominant polycystic kidney disease in the European Union.Cynthia Willey, Jaime D. Blais, Anthony K. Hall, Holly B. Krasa, Andrew Makin
Nephrology, Dialysis, Transplantation. 2016-06-19
Press Mentions
Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s SyndromeOctober 28th, 2024- Chutes & Ladders—J&J CEO Gorsky to Step Aside, Handing World's Largest Pharma to COVID-19 Navigator DuatoAugust 20th, 2021
- Sparrow Pharmaceuticals Expands Executive Leadership with Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and QualityAugust 17th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
